Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Decline in Short Interest

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) saw a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 3,050,000 shares, a decrease of 14.1% from the January 31st total of 3,550,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is presently 2.7 days.

Oncolytics Biotech Trading Down 6.3 %

Shares of NASDAQ ONCY traded down $0.05 during midday trading on Friday, reaching $0.69. The company had a trading volume of 370,217 shares, compared to its average volume of 1,402,154. The business's 50-day simple moving average is $0.79 and its 200 day simple moving average is $0.93. The stock has a market cap of $58.89 million, a P/E ratio of -2.55 and a beta of 1.18. Oncolytics Biotech has a 1 year low of $0.60 and a 1 year high of $1.53.

Analyst Ratings Changes

A number of equities research analysts recently commented on ONCY shares. HC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of Oncolytics Biotech in a research report on Monday, February 3rd. Raymond James raised shares of Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th. Finally, Leede Financial cut shares of Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in shares of Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock worth $61,000 after buying an additional 24,997 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Oncolytics Biotech by 15.0% in the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock worth $186,000 after buying an additional 26,069 shares during the last quarter. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech in the fourth quarter worth $27,000. National Bank of Canada FI raised its holdings in shares of Oncolytics Biotech by 199.6% in the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock worth $60,000 after buying an additional 42,955 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech during the fourth quarter worth $90,000. Hedge funds and other institutional investors own 6.82% of the company's stock.

Remove Ads

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.